Sarclisa was added to the National Comprehensive Cancer Network (NCCN) guidelines for non-transplant multiple myeloma candidates as a category 1 (preferred) option alongside VRd and Darzalex plus ...

The treatment landscape for multiple myeloma has shifted since European ... reviewed the treatment landscape at the National Comprehensive Cancer Network (NCCN) 2023 Annual Conference.

Cancer patients may have an increased risk of developing second primary malignancies after immune checkpoint inhibitor therapy.

Researchers have demonstrated the potential of the innovative optical genome mapping (OGM) technique for the diagnosis, ...

The National Comprehensive Cancer Network celebrated its 30 th anniversary with a series of presentations on cancer care practice changes-in both treatment and administration-plus new research, and ...